Early online
Real-world effectiveness of Ad26.COV2.S or BNT162b2 booster vaccines against severe COVID-19 in adults who received a primary dose of Ad26.COV2.S in South Africa during the Delta period: A retrospective cohort study using medical scheme data
DOI:
https://doi.org/10.7196/Keywords:
COVID-19, SARS-CoV-2, vaccine effectiveness, Ad26.COV2.S vaccine, variants of concern, ancestral vaccine, heterologous boosting, homologous boosting, South Africa, Sisonke study, health workersAbstract
Background. From March 2020 to June 2022, South Africa (SA) confronted successive waves of COVID‐19, each linked to emerging SARS‐CoV‐2 variants. Vaccines played a critical role in preventing severe disease and death, but as new SARS‐CoV‐2 variants emerged, with increasing breakthrough infections, questions arose about the real‐world effectiveness of first‐generation vaccines containing the ancestral strain against evolving variants including Delta and Omicron BA.1 and BA.4/5 SARS‐CoV‐2.
Objectives. To assess the real‐world effectiveness of ancestral strain booster doses (either Ad26.COV2.S or BNT162b2) in preventing severe COVID‐19 outcomes, including hospitalisation, admission to critical care and death, among essential workers in SA who received a primary dose of Ad26.COV2.S against emerging SARS‐CoV‐2 variants.
Methods. A retrospective cohort study was conducted using data from a large private health insurance scheme. Individuals who received a single dose of Ad26.COV2.S as their primary vaccination were included. Time‐varying Cox regression models were used to assess the effectiveness of boosting with either Ad26.COV2.S or BNT162b2 v. not boosting against severe COVID‐19 outcomes associated with emerging variants, adjusting for various demographic and clinical factors.
Results. By August 2021, a total of 407 961 individuals received a first dose of Ad26.COV2.S, of whom 350 688 were eligible for and 332 286 included in the vaccine effectiveness (VE) analysis. Of these, 206 359 (62%) received no further doses, while 113 957 (34%) received a second dose of Ad26.COV2.S and 11 970 (4%) received a second dose of BNT162b2 by August 2022. During the follow‐up period (November 2021 ‐ August 2022), 1 125 COVID‐19‐related hospital admissions, 198 admissions to critical care and 41 COVID‐19‐related deaths were recorded. Adjusted relative VE against severe outcomes was 34% (95% confidence interval (CI) 19 ‐ 45) for hospital admission, 51% (95% CI 22 ‐ 70) for critical care admission, and 89% (95% CI 13 ‐ 98) for COVID‐19‐ related death.
Conclusion. While most participants remained unboosted, administration of either ancestral strain Ad26.COV2.S or BNT162b2 vaccination provided protection against severe COVID‐19 outcomes among essential workers in SA during the dominance of the Omicron BA.1 and BA.4/5 variants, demonstrating cross‐strain protection.
References
References
Maslo, C., et al., Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. JAMA, 2022. 327(6): p. 583-584.
Abdullah, F., et al., Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. Int J Infect Dis, 2022. 116: p. 38-42.
Jassat, W., et al., Trends in cases, hospitalizations, and mortality related to the omicron BA. 4/BA. 5 subvariants in South Africa. Clinical Infectious Diseases, 2023. 76(8): p. 1468-1475.
Madhi, S.A., et al., Population immunity and Covid-19 severity with Omicron variant in South Africa. New England Journal of Medicine, 2022. 386(14): p. 1314-1326.
Grana, C., et al., Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev, 2022. 12(12): p. CD015477.
Madhi, S.A., et al., Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. N Engl J Med, 2021. 384(20): p. 1885-1898.
Sadoff, J., et al., Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med, 2021. 384(23): p. 2187-2201.
Bekker, L.G., et al., Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet, 2022. 399(10330): p. 1141-1153.
Oliver SE, W.M., See I, et al., Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices — United States, December 2021. . MMWR Morb Mortal Wkly Rep 2022. 71: p. 90-95.
Zeng, B., et al., Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis. BMC Med, 2022. 20(1): p. 200.
Katikireddi, S.V., et al., Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Lancet, 2022. 399(10319): p. 25-35.
Hardt, K., et al., Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2. S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases, 2022. 22(12): p. 1703-1715.
Gray, G., et al., Effectiveness of Ad26. COV2. S and BNT162b2 vaccines against Omicron variant in South Africa. New England Journal of Medicine, 2022. 386(23): p. 2243-2245.
Cuschieri, S., The STROBE guidelines. Saudi journal of anaesthesia, 2019. 13(Suppl 1): p. S31-S34.
Fintzi, J. and D. Follmann, Assessing vaccine durability in randomized trials following placebo crossover. Statistics in Medicine, 2021. 40(27): p. 5983-6007.
Lund, L.C., et al., Cox regression using a calendar time scale was unbiased in simulations of COVID-19 vaccine effectiveness & safety. Journal of Clinical Epidemiology, 2023. 156: p. 127-136.
Johnstone, S.L., et al., Effectiveness of BNT162b2 and Ad. COV2. S vaccines against COVID-19-related hospitalisation among adult members of a private health insurance scheme in South Africa during the Delta and Omicron periods: a test-negative case-control study. 2023.
Mohammed, H., et al., A systematic review and meta-analysis on the real-world effectiveness of COVID-19 vaccines against infection, symptomatic and severe COVID-19 disease caused by the omicron variant (B. 1.1. 529). Vaccines, 2023. 11(2): p. 224.
Atmar, R.L., et al., Homologous and Heterologous Covid-19 Booster Vaccinations. N Engl J Med, 2022. 386(11): p. 1046-1057.
Sablerolles, R.S.G., et al., Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming. N Engl J Med, 2022. 386(10): p. 951-963.
Mayr, F.B., et al., Effectiveness of homologous or heterologous Covid-19 boosters in veterans. New England Journal of Medicine, 2022. 386(14): p. 1375-1377.
Accorsi, E.K., et al., Effectiveness of homologous and heterologous Covid-19 boosters against Omicron. New England Journal of Medicine, 2022. 386(25): p. 2433-2435.
Kompaniyets, L., et al., Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period—United States, 1 January 2022 to 31 March 2022. Clinical Infectious Diseases, 2023. 76(10): p. 1753-1760.
Meeraus, W., et al., COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron. Vaccine, 2023. 41(42): p. 6366-6378.
Galanis, P., et al., Predictors of COVID-19 vaccination uptake and reasons for decline of vaccination: a systematic review. MedRxiv, 2021: p. 2021.07. 28.21261261.
Yan, E., et al., Predictors of COVID-19 actual vaccine uptake in Hong Kong: A longitudinal population-based survey. SSM Popul Health, 2022. 18: p. 101130.
Maughan-Brown, B., et al., Predictors of COVID-19 vaccine uptake among adults in South Africa: multimethod evidence from a population-based longitudinal study. BMJ Global Health, 2023. 8(8): p. e012433.
Barouch, D.H., Franklin H. Epstein Lecture: Covid-19 Vaccines—Immunity, Variants, Boosters. The New England Journal of Medicine, 2022.
Zimmer, C. and N. Weiland, People who received a J.&J. vaccine may be better off with a Moderna or Pfizer booster, a study finds, in The New York Times. 2021: New York.
Organization, W.H. Global strategic preparedness and response plan launched by WHO to contain mpox outbreak. 2024 26/08/2024]; Available from: https://www.who.int/news/item/26-08-2024-global-strategic-preparedness-and-response-plan-launched-by-who-to-contain-mpox-outbreak/.
Downloads
Published
License
Copyright (c) 2025 L Fairall, N Yende-Zuma, Tarylee Reddy, N Garrett, A Goga, S Bennet, N Folb, I Seocharan, S Mametja, M Semenya, S R N Simelane, Prof. Linda-Gail Bekker, G E Gray
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Licensing Information
The SAMJ is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository.
Publishing Rights
Authors grant the Publisher the exclusive right to publish, display, reproduce and/or distribute the Work in print and electronic format and in any medium known or hereafter developed, including for commercial use. The Author also agrees that the Publisher may retain in print or electronic format more than one copy of the Work for the purpose of preservation, security and back-up.
